Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome

American Journal of Physiology - Endocrinology and Metabolism

Volumn 297, Issue 1, 2009, Pages

  Yang, Guang ^a   Badeanlou, Leylla ^a   Bielawski, Jacek ^b   Roberts, Amanda J ^c   Hannun, Yusuf A ^b   Samad, Fahumiya ^a  

^a TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Insulin resistance; Leptin resistance; Monocyte chemoattactant protein 1; Plasminogen activator inhibitor 1; Sphingolipids; Suppressor of cytokine signaling 3; Tumor necrosis factor

Indexed keywords

CERAMIDE; INSULIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MYRISTIC ACID; PLASMINOGEN ACTIVATOR INHIBITOR 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; TUMOR NECROSIS FACTOR ALPHA; UNCOUPLING PROTEIN 3;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; BODY WEIGHT; CONTROLLED STUDY; ENERGY EXPENDITURE; ENERGY METABOLISM; FATTY LIVER; GLUCOSE HOMEOSTASIS; LIPID DIET; LIVER; METABOLIC SYNDROME X; MOUSE; MUSCLE; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ADIPOSE TISSUE; ANIMALS; BODY WEIGHT; CERAMIDES; ENERGY METABOLISM; FATTY ACIDS, MONOUNSATURATED; ION CHANNELS; LYSOPHOSPHOLIPIDS; MALE; METABOLIC SYNDROME X; MICE; MICE, INBRED C57BL; MITOCHONDRIAL PROTEINS; OBESITY; ORGAN SIZE; SPHINGOLIPIDS; SPHINGOSINE; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 67650096801     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.91014.2008     Document Type: Article

References (59)

1. Axelsson J, Heimburger O, Lindholm B, Stenvinkel P. Adipose tissue and its relation to inflammation: the role of adipokines. J Ren Nutr 15: 131-136, 2005.
2. Bielawski J, Szulc ZM, Hannun YA, Bielawska A. Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods 39: 82-91, 2006.
3. Cernkovich ER, Deng J, Bond MC, Combs TP, Harp JB. Adipose-specific disruption of signal transducer and activator of transcription 3 increases body weight and adiposity. Endocrinology 149: 1581-1590, 2008.
4. Chang L, Chiang SH, Saltiel AR. Insulin signaling and the regulation of glucose transport. Mol Med 10: 65-71, 2004.
5. De TB, Smith LH, Vaughan DE. Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Curr Opin Pharmacol 5: 149-154, 2005.
6. Dellas C, Loskutoff DJ. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 93: 631-640, 2005.
7. Emanuelli B, Peraldi P, Filloux C, Chavey C, Freidinger K, Hilton DJ, Hotamisligil GS, Van OE. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem 276: 47944-47949, 2001.
8. Foster LJ, Chan QW. Lipid raft proteomics: more than just detergent-resistant membranes. Subcell Biochem 43: 35-47, 2007.
9. Friedman J. Fat in all the wrong places. Nature 415: 268-269, 2002.
10. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 395: 763-770, 1998.
11. Friedman JM, Leibel RL. Tackling a weighty problem. Cell 69: 217-220, 1992.
12. Gosling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG, Rollins BJ, Charo IF. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 103: 773-778, 1999.
13. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 2: 275-281, 1998.
14. Hannun YA, Obeid LM. The ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J Biol Chem 277: 25847-25850, 2002.
15. Holland WL, Brozinick JT, Wang LP, Hawkins ED, Sargent KM, Liu Y, Narra K, Hoehn KL, Knotts TA, Siesky A, Nelson DH, Karathanasis SK, Fontenot GK, Birnbaum MJ, Summers SA. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab 5: 167-179, 2007.
16. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259: 87-91, 1993.
17. Howard JK, Flier JS. Attenuation of leptin and insulin signaling by SOCS proteins. Trends Endocrinol Metab 17: 365-371, 2006.
18. Ikonen E, Vainio S. Lipid microdomains and insulin resistance: is there a connection? Sci STKE 2005: e3, 2005.
19. Juhan-Vague I, Alessi MC, Mavri A, Morange PE. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 1: 1575-1579, 2003.
20. Kamei N, Tobe K, Suzuki R, Ohsugi M, Watanabe T, Kubota N, Ohtsuka-Kowatari N, Kumagai K, Sakamoto K, Kobayashi M, Yamauchi T, Ueki K, Oishi Y, Nishimura S, Manabe I, Hashimoto H, Ohnishi Y, Ogata H, Tokuyama K, Tsunoda M, Ide T, Murakami K, Nagai R, Kadowaki T. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 281: 26602-26614, 2006.
21. Kanatani Y, Usui I, Ishizuka K, Bukhari A, Fujisaka S, Urakaze M, Haruta T, Kishimoto T, Naka T, Kobayashi M. Effects of pioglitazone on suppressor of cytokine signaling 3 expression: potential mechanisms for its effects on insulin sensitivity and adiponectin expression. Diabetes 56: 795-803, 2007.
22. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, Kitazawa S, Miyachi H, Maeda S, Egashira K, Kasuga M. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116: 1494-1505, 2006.
23. Kolak M, Westerbacka J, Velagapudi VR, Wagsater D, Yetukuri L, Makkonen J, Rissanen A, Hakkinen AM, Lindell M, Bergholm R, Hamsten A, Eriksson P, Fisher RM, Oresic M, Yki-Jarvinen H. Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes 56: 1960-1968, 2007.
24. Kozak LP, Harper ME. Mitochondrial uncoupling proteins in energy expenditure. Annu Rev Nutr 20: 339-363, 2000.
25. Kraegen EW, Cooney GJ, Ye JM, Thompson AL, Furler SM. The role of lipids in the pathogenesis of muscle insulin resistance and beta cell failure in type II diabetes and obesity. Exp Clin Endocrinol Diabetes 109, Suppl 2: S189-S201, 2001.
26. Le BO, Petroulakis E, Paglialunga S, Poulin F, Richard D, Cianflone K, Sonenberg N. Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. J Clin Invest 117: 387-396, 2007.
27. Lebrun P, Van OE. SOCS proteins causing trouble in insulin action. Acta Physiol (Oxf) 192: 29-36, 2008.
28. Lelliott C, Vidal-Puig AJ. Lipotoxicity, an imbalance between lipogenesis de novo and fatty acid oxidation. Int J Obes Relat Metab Disord 28, Suppl 4: S22-S28, 2004.
29. Loskutoff DJ, Samad F. The adipocyte and hemostatic balance in obesity: Studies of PAI-1. Arterioscler Thromb Vasc Biol 18: 1-6, 1998.
30. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 117: 175-184, 2007.
31. Lumeng CN, Deyoung SM, Bodzin JL, Saltiel AR. Increased inflammatory properties of adipose tissue macrophages recruited during dietinduced obesity. Diabetes 56: 16-23, 2007.
32. McGarry JD. Banting lecture 2001. Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51: 7-18, 2002.
33. Narazaki M, Fujimoto M, Matsumoto T, Morita Y, Saito H, Kajita T, Yoshizaki K, Naka T, Kishimoto T. Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling. Proc Natl Acad Sci USA 95: 13130-13134, 1998.
34. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 88: 1121-1127, 1991.
35. Nicholls DG, Locke RM. Thermogenic mechanisms in brown fat. Physiol Rev 64: 1-64, 1984.
36. Ohanian J, Ohanian V. Sphingolipids in mammalian cell signalling. Cell Mol Life Sci 58: 2053-2068, 2001.
37. Palasciano G, Moschetta A, Palmieri VO, Grattagliano I, Iacobellis G, Portincasa P. Non-alcoholic fatty liver disease in the metabolic syndrome. Curr Pharm Des 13: 2193-2198, 2007.
38. Pandey M, Tuncman G, Hotamisligil GS, Samad F. Divergent roles for p55 and p75 TNF-α receptors in the induction of plasminogen activator inhibitor-1. Am J Pathol 162: 933-941, 2003.
39. Pewzner-Jung Y, Ben-Dor S, Futerman AH. When do Lasses (longevity assurance genes) become CerS (ceramide synthases)?: insights into the regulation of ceramide synthesis. J Biol Chem 281: 25001-25005, 2006.
40. Ruvolo PP. Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharmacol Res 47: 383-392, 2003.
41. Samad F. Contribution of sphingolipids to the pathogenesis of obesity. Future Lipidol 2: 625-639, 2008.
42. Samad F, Hester KD, Yang G, Hannun YA, Bielawski J. Altered adipose and plasma sphingolipid metabolism in obesity: a potential mechanism for cardiovascular and metabolic risk. Diabetes 55: 2579-2587, 2006.
43. Samad F, Yamamoto K, Loskutoff DJ. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo: Induction by tumor necrosis factor-α and lipopolysaccharide. J Clin Invest 97: 37-46, 1996.
44. Samad F. Contribution of sphingolipids to the pathogenesis of obesity. Future Lipidology 2: 625-639, 2007.
45. Sethi JK, Xu H, Uysal KT, Wiesbrock SM, Scheja L, Hotamisligil GS. Characterisation of receptor-specific TNFα functions in adipocyte cell lines lacking type 1 and 2 TNF receptors. FEBS Lett 469: 77-82, 2000.
46. Shah C, Yang G, Lee I, Bielawski J, Hannun YA, Samad F. Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1. J Biol Chem 283: 13538-13548, 2008.
47. Soeda S, Honda O, Shimeno H, Nagamatsu A. Sphingomyelinase and cell-permeable ceramide analogs increase the release of plasminogen activator inhibitor-1 from cultured endothelial cells. Thromb Res 80: 509-518, 1995.
48. Steinberg GR, McAinch AJ, Chen MB, O'Brien PE, Dixon JB, Cameron-Smith D, Kemp BE. The suppressor of cytokine signaling 3 inhibits leptin activation of AMP-kinase in cultured skeletal muscle of obese humans. J Clin Endocrinol Metab 91: 3592-3597, 2006.
49. Summers SA. Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res 45: 42-72, 2006.
50. Ueki K, Kondo T, Tseng YH, Kahn CR. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci USA 101: 10422-10427, 2004.
51. Unger RH. Minireview. Weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 144: 5159-5165, 2003.
52. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature 389: 610-614, 1997.
53. Wang MY, Orci L, Ravazzola M, Unger RH. Fat storage in adipocytes requires inactivation of leptin's paracrine activity: implications for treatment of human obesity. Proc Natl Acad Sci USA 102: 18011-18016, 2005.
54. Wang ZW, Pan WT, Lee Y, Kakuma T, Zhou YT, Unger RH. The role of leptin resistance in the lipid abnormalities of aging. FASEB J 15: 108-114, 2001.
55. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, Vaddi K, Charo I, Leibel RL, Ferrante AW. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 116: 115-124, 2006.
56. Yang R, Wilcox DM, Haasch DL, Jung PM, Nguyen PT, Voorbach MJ, Doktor S, Brodjian S, Bush EN, Lin E, Jacobson PB, Collins CA, Landschulz KT, Trevillyan JM, Rondinone CM, Surowy TK. Liver-specific knockdown of JNK1 up-regulates proliferator-activated receptor gamma coactivator 1 beta and increases plasma triglyceride despite reduced glucose and insulin levels in diet-induced obese mice. J Biol Chem 282: 22765-22774, 2007.
57. Yasukawa H, Misawa H, Sakamoto H, Masuhara M, Sasaki A, Wakioka T, Ohtsuka S, Imaizumi T, Matsuda T, Ihle JN, Yoshimura A. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J 18: 1309-1320, 1999.
58. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425-432, 1994.
59. Zheng W, Kollmeyer J, Symolon H, Momin A, Munter E, Wang E, Kelly S, Allegood JC, Liu Y, Peng Q, Ramaraju H, Sullards MC, Cabot M, Merrill AH Jr. Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy. Biochim Biophys Acta 1758: 1864-1884, 2006.